Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics

10-May-2017

Kit increases efficiency of residual protein A ligand detection

Uppsala, Sweden, May 10 , 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its Gyrolab™ Protein A Kit.

The new Protein A Kit offers increased efficiency and throughput for quantification of residual Protein A ligands, with 96 microstructures, this next generation in Protein A detection and quantification offers double the capacity of the previous Gyrolab Mixing CD. Two ready to use versions of the kit – Native Protein A and MabSelect™ Sure– are designed for use with Gyrolab systems, and include an enhanced protocol for automated acid pretreatment of harvested samples from downstream purification of biotherapeutics.

Determination of residual protein A is an essential regulatory requirement for the safety evaluation of biotherapeutics. During the purification of biotherapeutics, Protein A can leach from the chromatography support and co-elute with the therapeutic antibody product. If bound to immunoglobulins, Protein A can increase the risk of adverse reactions.

Mattias Bylund, Product Manager, Gyros Protein Technologies, said: “We are pleased to offer our customers this improved version of our Protein A Kit, enabling them to easily and quickly quantify residual Protein A ligands in the presence of high IgG concentrations. The launch of the new kits forms part of Gyros Protein Technologies’ commitment to developing immunoassay solutions for the bioprocess market.”

 

END

Notes to editors

protein A kit with 96 CD

 

 

 

 

For a high resolution image please contact Zyme Communications

 


Media contact:
Katie Odgaard
Zyme Communications
Tel: +44(0)7787 502 947
Email: Katie.odgaard@zymecommunications.com

About Gyros Protein Technologies 

Gyros Protein Technologies, enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab™xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.